Cat. No.: HY-100002

ML162

18 Cited Publications

Avis client

Based on 18 publication(s) in Google Scholar

ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.52%
CAS No.: 1035072-16-2
Formule: C₂₃H₂₂Cl₂N₂O₃S
Masse moléculaire:477.40

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

ML162 Chemical Structure

CAS No.: 1035072-16-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (18)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines^[1]^[2]

IC₅₀ & Target

GPX4

Voir tous les produits spécifiques à Isoform Glutathione Peroxidase :

GPX1
GPX4

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	2.52 μM Compound: 5; ML162	Cytotoxicity against human 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34506134]
4T1	IC₅₀	2.52 μM Compound: 5; ML162	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34506134]
A549	IC₅₀	2.09 μM Compound: ML162	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
ASPC1	IC₅₀	142 nM Compound: ML162	Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]
BJ	IC₅₀	34 nM Compound: 1a	Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay Cytotoxicity against human BJ cells expressing HRAS G12V mutant with alternative oncogenic constructs after 48 hrs by alamar blue assay	[PMID: 22297109]
BT-549	IC₅₀	0.65 μM Compound: ML162	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 37452764]
HCT-116	IC₅₀	3.71 nM Compound: ML162	Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]
HCT-116	IC₅₀	4.14 μM Compound: ML162	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
HepG2	IC₅₀	3.71 μM Compound: ML162	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
HT-1080	IC₅₀	0.06 μM Compound: ML162	Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38838547]
HT-1080	IC₅₀	0.6 μM Compound: ML162	Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38593589]
HT-1080	IC₅₀	0.66 μM Compound: 5; ML162	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34506134]
HT-1080	IC₅₀	0.76 μM Compound: ML162	Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HT-1080 cells incubated for 48 hrs by CCK-8 assay	[PMID: 39230973]
HT-1080	IC₅₀	2 μM Compound: ML162	Cytotoxicity against human HT-1080 cells incubated for 48 hrs in presence of Fer-1 by CCK-8 assay Cytotoxicity against human HT-1080 cells incubated for 48 hrs in presence of Fer-1 by CCK-8 assay	[PMID: 39230973]
HT-1080	IC₅₀	7.31 μM Compound: 5; ML162	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs in presence of Fer-1 by MTT assay Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs in presence of Fer-1 by MTT assay	[PMID: 34506134]
MCF7	IC₅₀	10.1 μM Compound: 5; ML162	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34506134]
MDA-MB-231	IC₅₀	0.16 μM Compound: ML162	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 37452764]
MDA-MB-231	IC₅₀	2.27 μM Compound: ML162	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
MDA-MB-231	IC₅₀	2.56 μM Compound: ML162	Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of ferroptosis inhibitor, ferrostatin-1 by MTT assay Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of ferroptosis inhibitor, ferrostatin-1 by MTT assay	[PMID: 37452764]
MDA-MB-468	IC₅₀	0.12 μM Compound: ML162	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 37452764]
NCI-H522	IC₅₀	14 nM Compound: ML162	Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38265413]

In Vitro

ML162 (compound 1a) shows nanomolar potencies against two HRAS^G12V expressing cell lines, with IC₅₀ values of 25 nM and 578 nM for HRASG12V-expressing and wild-type BJ fibroblasts, respectively^[1].
ML162 (8 μM; 24 hours) treatment increases the expression of p62 and Nrf2 in chemoresistant HN3R and HN3-rslR cells, inactivates Keap1, and increases expression of the phospho-PERK-ATF4-SESN2 pathway^[2].
ML162 induces the head and neck cancer (HNC) cell death to varying degrees, with parental HN3 cells more sensitive and cisplatin-resistant (HN3R) and acquired RSL3-resistant (HN3-rslR) cells less sensitive^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

HN3R cells
Concentration:

8 μM
Incubation Time:

24 hours
Result:

Increased the expression of p62 and Nrf2 in chemoresistant HN3R and HN3-rslR cells.

Chemical Information

CAS No. 1035072-16-2
Appearance Solid
Masse moléculaire 477.40
Formule C₂₃H₂₂Cl₂N₂O₃S
Color White to light yellow
SMILES

O=C(CCl)N(C(C1=CC=CS1)C(NCCC2=CC=CC=C2)=O)C3=CC=C(OC)C(Cl)=C3
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (18)

All Cell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Nat Cancer

Palmitoylation of GPX4 via the targetable ZDHHC8 determines ferroptosis sensitivity and antitumor immunity. [Abstract]

2025 May;6(5):768-785. PMID: 40108413

ML162 purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2025 May;6(5):768-785. [Abstract]

The cell viability of mock or ZDHHC8-KO HT-1080 cells treated with DMSO, RSL3 (0.1 μM), ML162 (0.1 μM), IKE (1 μM) or IFNγ (20 ng/ml) plus AA (20 μM) together with or without Fer-1 (2 μM). For RSL3, ML162 and IKE, cells were treated for 24 h, and for IFNγ plus AA, cells were treated for 48 h.
Nat Cell Biol

Full-length GSDME mediates pyroptosis independent from cleavage. [Abstract]

2024 Sep;26(9):1545-1557. PMID: 38997456
Autophagy

Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. [Abstract]

2026 Feb 15:1-19. PMID: 41612599
Cell Discov

Genetic tracing uncovers the importance of epithelial-to-mesenchymal transition in small cell lung cancer chemotherapy resistance but not metastasis. [Abstract]

2024 Jun 4;10(1):60. PMID: 38834595

ML162 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2024 Jun 4;10(1):60. [Abstract]

ML162 (0.075 µM; 72 h) alone or in combination with E/P significantly inhibits H526R cell growth.
Mol Cell

SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation. [Abstract]

2023 Dec 7;83(23):4352-4369.e8. PMID: 38016474

ML162 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2023 Dec 7;83(23):4352-4369.e8. [Abstract]

Western blot analysis of GSTP1 protein levels in HT 1080 cells treated with ascending doses of ML162 (0.5-3 μM; 1-4 h) or for the different time durations (top). Quantitative results of three independent replicates (below).
Sci Adv

Metabolic rewiring driven by phosphoglycolate phosphatase deletion inhibits ferroptosis. [Abstract]

2026 May 29;12(22):eaeb2368. PMID: 42213853
Cell Death Dis

Inhibition of mitochondrial complex I induces mitochondrial ferroptosis by regulating CoQH2 levels in cancer. [Abstract]

2025 Apr 5;16(1):254. PMID: 40185704

ML162 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 5;16(1):254. [Abstract]

Cell viability of Huh7 or NCI-H23 cells treated with RSL3 (0.5 μM) or ML162 (0.5 μM), with or without ROT (10 μM) for 8 h, following pretreatment with NADH (1 mM) for 24 h.
J Immunother Cancer

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma. [Abstract]

2024 Nov 24;12(11):e009805. PMID: 39581704
Phytomedicine

Columbianadin targets TRIM7 to maintain P2X7 palmitoylation, inhibiting cuproptosis in synovial M2 macrophages. [Abstract]

2025 Oct:146:157091. PMID: 40768810
Oncogene

CAPRIN1-mediated sequestration of NCOA4 mRNA into stress granules drives sorafenib resistance in hepatocellular carcinoma. [Abstract]

2026 May;45(16):1411-1424. PMID: 41896589
ACS Appl Mater Interfaces

Photodynamic Therapy Initiated Ferrotherapy of Self-Delivery Nanomedicine to Amplify Lipid Peroxidation via GPX4 Inactivation. [Abstract]

2022 Dec 7;14(48):53501-53510. PMID: 36399048
J Ethnopharmacol

Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]

2026 Feb 28:357:120890. PMID: 41232632
Biochem Pharmacol

Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells. [Abstract]

2024 May:223:116194. PMID: 38583812
Cancer Biol Ther

Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. [Abstract]

2026 Dec 31;27(1):2676474. PMID: 42189063
Am J Cancer Res

SIRT6 drives sensitivity to ferroptosis in anaplastic thyroid cancer through NCOA4-dependent autophagy. [Abstract]

2023 Feb 15;13(2):464-474. PMID: 36895980

ML162 purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2023 Feb 15;13(2):464-474. [Abstract]

Viability of CAL62 cells treated with different FINs (Erastin, 20 μM; ML210, 2 μM; ML162, 2 μM; all treated for 24 h).
Translational Dental Research

2026 Apr 15.
SSRN

2025 Dec 2.
Cornell University

2025.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (209.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0947 mL

10.4734 mL

20.9468 mL

5 mM

0.4189 mL

2.0947 mL

4.1894 mL

10 mM

0.2095 mL

1.0473 mL

2.0947 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Michel Weïwer, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6. [Content Brief]

[2]. Daiha Shin, et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018 Dec;129:454-462. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0947 mL	10.4734 mL	20.9468 mL	52.3670 mL
	5 mM	0.4189 mL	2.0947 mL	4.1894 mL	10.4734 mL
	10 mM	0.2095 mL	1.0473 mL	2.0947 mL	5.2367 mL
	15 mM	0.1396 mL	0.6982 mL	1.3965 mL	3.4911 mL
	20 mM	0.1047 mL	0.5237 mL	1.0473 mL	2.6183 mL
	25 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0947 mL
	30 mM	0.0698 mL	0.3491 mL	0.6982 mL	1.7456 mL
	40 mM	0.0524 mL	0.2618 mL	0.5237 mL	1.3092 mL
	50 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0473 mL
	60 mM	0.0349 mL	0.1746 mL	0.3491 mL	0.8728 mL
	80 mM	0.0262 mL	0.1309 mL	0.2618 mL	0.6546 mL
	100 mM	0.0209 mL	0.1047 mL	0.2095 mL	0.5237 mL

Keywords

ML162

18 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

ML162

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Cancer Metabolism Compound Library

Cuproptosis Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Aging Compound Library Mini

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) ML162

Voir tous les produits spécifiques à Isoform Glutathione Peroxidase

Activité biologique

Chemical Information

Publications (18)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ML162

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Cancer Metabolism Compound Library

Cuproptosis Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Aging Compound Library Mini

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) ML162

Voir tous les produits spécifiques à Isoform Glutathione Peroxidase

Activité biologique

Chemical Information

Publications (18)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ML162 Related Classifications

HY-100002 Related Classifications